Transcriptome analysis of grey and white matter cortical tissue in multiple system atrophy

被引:0
作者
James D. Mills
Woojin S. Kim
Glenda M. Halliday
Michael Janitz
机构
[1] University of New South Wales,School of Biotechnology and Biomolecular Sciences
[2] Neuroscience Research Australia,School of Medical Sciences
[3] University of New South Wales,undefined
来源
neurogenetics | 2015年 / 16卷
关键词
Multiple system atrophy; Transcriptome sequencing; White and grey matter; Haemoglobin genes; Long intervening non-coding RNA;
D O I
暂无
中图分类号
学科分类号
摘要
Multiple system atrophy (MSA) is a distinct member of a group of neurodegenerative diseases known as α-synucleinopathies, which are characterized by the presence of aggregated α-synuclein in the brain. MSA is unique in that the principal site for α-synuclein deposition is in the oligodendrocytes rather than neurons. The cause of MSA is unknown, and the pathogenesis of MSA is still largely speculative. Brain transcriptome perturbations during the onset and progression of MSA are mostly unknown. Using RNA sequencing, we performed a comparative transcriptome profiling analysis of the grey matter (GM) and white matter (WM) of the frontal cortex of MSA and control brains. The transcriptome sequencing revealed increased expression of the alpha and beta haemoglobin genes in MSA WM, decreased expression of the transthyretin (TTR) gene in MSA GM and numerous region-specific long intervening non-coding RNAs (lincRNAs). In contrast, we observed only moderate changes in the expression patterns of the α-synuclein (SNCA) gene, which confirmed previous observations by other research groups. Our study suggests that at the transcriptional level, MSA pathology may be related to increased iron levels in WM and perturbations of the non-coding fraction of the transcriptome.
引用
收藏
页码:107 / 122
页数:15
相关论文
共 435 条
[1]  
Wenning GK(2013)The natural history of multiple system atrophy: a prospective European cohort study Lancet Neurol 12 264-274
[2]  
Geser F(2011)Neuropathology underlying clinical variability in patients with synucleinopathies Acta Neuropathol 122 187-204
[3]  
Krismer F(2014)Lipid dysfunction and pathogenesis of multiple system atrophy Acta Neuropathol Commun 2 15-693
[4]  
Seppi K(2011)Glial dysfunction in the pathogenesis of alpha-synucleinopathies: emerging concepts Acta Neuropathol 121 675-586
[5]  
Duerr S(2013)The role of glia in alpha-synucleinopathies Mol Neurobiol 47 575-345
[6]  
Boesch S(2006)Cellular pathology in multiple system atrophy Neuropathology 26 338-246
[7]  
Kollensperger M(2008)Multiple system atrophy: a primary oligodendrogliopathy Ann Neurol 64 239-646
[8]  
Goebel G(2008)LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions Acta Neuropathol 116 639-244
[9]  
Pfeiffer KP(2013)Mutations in COQ2 in familial and sporadic multiple-system atrophy N Engl J Med 369 233-467
[10]  
Barone P(2006)The alpha-synuclein gene in multiple system atrophy J Neurol Neurosurg Psychiatry 77 464-170